Cerebral Gamma-aminobutyric Acid Research Articles

Brain glutathione and GABA+ levels in autistic children.

Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by social communication challenges and repetitive behaviors. Altered neurometabolite levels, including glutathione (GSH) and gamma-aminobutyric acid (GABA), have been proposed as potential contributors to the biology underlying ASD. This study investigated whether cerebral GSH or GABA levels differ between a cohort of children aged 8-12 years with ASD (n = 52) and typically developing children (TDC, n = 49). A comprehensive analysis of GSH and GABA levels in multiple brain regions, including the primary motor cortex (SM1), thalamus (Thal), medial prefrontal cortex (mPFC), and supplementary motor area (SMA), was conducted using single-voxel HERMES MR spectroscopy at 3T. The results revealed no significant differences in cerebral GSH or GABA levels between the ASD and TDC groups across all examined regions. These findings suggest that the concentrations of GSH (an important antioxidant and neuromodulator) and GABA (a major inhibitory neurotransmitter) do not exhibit marked alterations in children with ASD compared to TDC. A statistically significant positive correlation was observed between GABA levels in the SM1 and Thal regions with ADHD inattention scores. No significant correlation was found between metabolite levels and hyper/impulsive scores of ADHD, measures of core ASD symptoms (ADOS-2, SRS-P) or adaptive behavior (ABAS-2). While both GSH and GABA have been implicated in various neurological disorders, the current study provides valuable insights into the specific context of ASD and highlights the need for further research to explore other neurochemical alterations that may contribute to the pathophysiology of this complex disorder.

Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12months.

Cerebral glutamate and gamma-aminobutyric acid (GABA) levels might predict clinical outcome in individuals at ultrahigh risk (UHR) for psychosis but have previously primarily been investigated in smaller cohorts. We aimed to study whether baseline levels of glutamate and GABA in anterior cingulate cortex (ACC) and glutamate in thalamus could predict remission status and whether baseline metabolites differed in the remission versus the nonremission group. We also investigated the relationship between baseline metabolite levels and severity of clinical symptoms, functional outcome, and cognitive deficits at follow-up. About 124 UHR individuals were recruited at baseline. In this, 74 UHR individuals were clinically and cognitively assessed after 12months, while remission status was available for 81 (25 remission/56 nonremission). Glutamate and GABA levels were assessed at baseline using 3T proton magnetic resonance spectroscopy. Psychopathology, symptom severity, and remission were assessed with the Comprehensive Assessment of At-Risk Mental States and Clinical Global Impression and functional outcome with the Social and Occupational Functioning Assessment Scale. Cognitive function was estimated with the Cambridge Neuropsychological Test Automated Battery. There were no differences between baseline glutamate and GABA levels in subjects in the nonremission group compared with the remission group, and baseline metabolites could not predict remission status. However, higher baseline levels of GABA in ACC were associated with clinical global improvement (r=-0.34, N=51, p=0.01) in an explorative analysis. The variety in findings across studies suggests a probable multifactorial influence on clinical outcome in UHR individuals. Future studies should combine multimodal approaches to attempt prediction of long-term outcome.

Gamma-aminobutyric acid edited echo-planar spectroscopic imaging (EPSI) with MEGA-sLASER at 7T.

PurposeFor rapid spatial mapping of gamma‐aminobutyric acid (GABA) at the increased sensitivity and spectral separation for ultra‐high magnetic field strength (7 tesla [T]), an accelerated edited magnetic resonance spectroscopic imaging technique was developed and optimized for the human brain at 7 T.MethodsA MEGA‐sLASER sequence was used for GABA editing and volume selection to maximize editing efficiency and minimize chemical shift displacement errors. To accommodate the high bandwidth requirements at 7 T, a single‐shot echo planar readout was used for rapid simultaneous encoding of the temporal dimension and 1 spatial. B 0 and B 1 field aspects specific for 7 T were studied together with correction procedures, and feasibility of the EPSI MEGA‐sLASER technique was tested in vivo in 5 healthy subjects.ResultsLocalized edited spectra could be measured in all subjects giving spatial GABA signal distributions over a central brain region, having 45‐ to 50‐Hz spatial intervoxel B 0 field variations and up to 30% B 1 field deviations. MEGA editing was found unaffected by the B 0 inhomogeneities for the optimized sequence. The correction procedures reduced effects of intervoxel B0 inhomogeneities, corrected for spatial editing efficiency variations, and compensated for GABA resonance phase and frequency shifts from subtle motion and acquisition instabilities. The optimized oscillating echo‐planar gradient scheme permitted full spectral acquisition at 7 T and exhibited minimal spectral‐spatial ghosting effects for the selected brain region.ConclusionThe EPSI MEGA‐sLASER technique was shown to provide time‐efficient mapping of regional variations in cerebral GABA in a central volume of interest with spatial B 1 and B 0 field variations typical for 7 T.

Assessment of regional GABA A receptor binding using 18F-fluoroflumazenil positron emission tomography in spastic type cerebral palsy

Periventricular leukomalacia (PVL) due to hypoxic–ischemic insult to the immature brain, chorioamnionitis and maternal infection are the major etiological factors of spastic type cerebral palsy (CP). Despite advances in preventing and treating certain causes of CP, the number of patients has remained essentially unchanged and the pathophysiological mechanisms related to motor dysfunction remain poorly understood. In this study, statistical parametric mapping (SPM) analysis of cerebral gamma-aminobutyric acid (GABA) receptor PET imaging using [ 18F]-fluoroflumazenil showed increased GABA A receptor binding in the bilateral motor and visual cortices in spastic diplegia (SD) type CP patients ( n = 20) compared with normal controls ( n = 10). As GABA A receptor signaling modulates biological perception and production of movement, complex motor skills and use-dependent plasticity in the motor cortex, increased GABA A receptor binding in the motor cortex might play a important role in poor motor control. Decreased GABA A receptor binding was seen in the brain stem in SD CP patients, which appears to be related to spastic symptom.

Magnetic resonance spectroscopic measurement of cerebral gamma-aminobutyric acid concentrations in patients with bipolar disorders.

Animal models of depression and psychopharmacological mechanisms of action suggest the importance of the gamma-amino butyric acid (GABA) system in the pathophysiology of mood disorders. Mood stabilizers have overlapping effects on GABAergic neurotransmission, and antidepressant use has been associated with alterations in GABAB receptor function. Magnetic resonance spectroscopy (MRS) provides an opportunity to noninvasively assess cerebral GABA concentrations in anterior paralimbic circuits that have been implicated in mood disorders. In bipolar disorder patients and healthy control subjects, we used MRS with a modified GABA-edited point resolved spectroscopy sequence (TE 68 ms, TR 1500 ms, 512 averages, total scan time 26 min) to assess GABA in an 18-cm3 occipital voxel. In addition, in another cohort of bipolar disorder patients and healthy control subjects, we similarly assessed GABA in a 12.5-cm3 medial prefrontal/anterior cingulate (MPF/AC) voxel. The concentration of GABA was referenced to creatine (Cr) from unedited spectra. In bipolar patients and controls, we consistently detected 3.0 p.p.m. GABA peaks in occipital lobe and MPF/AC. In 16 bipolar (nine bipolar I and seven bipolar II) disorder patients, compared with six healthy control subjects, mean occipital GABA/Cr concentration was 61% higher. In addition, in 15 bipolar (five bipolar I, nine bipolar II, and one bipolar not otherwise specified) disorder patients, compared with six healthy control subjects, mean MPF/AC GABA/Cr concentration tended to be 41% higher. Patients with bipolar disorders may have increased cerebral GABA concentrations. Although this was more evident in the occipital lobe, MPC/AC GABA disturbance may be of greater potential interest in view the more established role of MPF/AC in affective processing. Additional studies are warranted to assess changes in GABAergic neurotransmission and the influences of diagnosis, mood state, and medication status in bipolar disorder patients.

Emotion‐Induced Myoclonic Absence‐Like Seizures in a Patient with Inv‐Dup(15) Syndrome: A Clinical, EEG, and Molecular Genetic Study

We have described a clinical EEG and molecular genetic study of a 9-year-old boy with inv-dup(15) syndrome in whom seizures were induced by emotionally gratifying stimuli. The reflex seizures began 5-20 s after the onset of repeated cheek-kissing from his mother or after viewing of pleasant or funny events. They were characterized by bilateral discharges involving mainly the temporal regions and evolving into myoclonic absence-like seizures. Nonemotional stimuli, such as a pinch, sucking or rubbing his cheeks, or the sound of the kiss alone, failed to provoke seizures. The seizures were resistant to antiepileptic (AED) treatments. Molecular genetic investigations revealed a correct methylation pattern of the chromosomes 15, and three copies (two maternal and one paternal) of the segment 15q11-q13, including the GABRb3 gene. We hypothesize that an overexpression of cerebral gamma-aminobutyric acid (GABA)-mediated inhibition accounts for the severe epilepsy that we observed in this patient.

An anaesthetic dose of ethanol inhibits cyclic AMP formation by altering the function of GS protein.

The effects of ethanol on cerebral gamma-aminobutyric acid (GABA)B receptor and its related signal transduction systems were studied. [3H]GABA binding to cerebral GABAB receptors in crude synaptic membranes from rat brain was unaffected by ethanol at concentrations up to 100 mM, although 100 mM ethanol suppressed not only the basal but also forskolin-stimulated cAMP formation in cerebral cortical membrane vesicles. The suppressive effect of baclofen and the stimulatory effect of forskolin on cAMP formation was also found to be unaltered by ethanol. Pretreatment of the membrane vesicles with islet-activating protein (IAP), which eliminates the function of Gi protein by its ribosylation, had no effect on the suppressive effects of ethanol on basal and forskolin-stimulated cAMP formation. In contrast, pretreatment of membrane vesicles with 'low pH', which is known to suppress the function of Gs protein, eliminated the suppressive effect of ethanol on cAMP formation. These results suggest that an anaesthetic dose of ethanol, which is below that necessary to cause changes in receptor binding, may not affect the functions of GABAB/Gi, G(O) protein/adenylate cyclase system, but suppresses cAMP formation systems which are coupled with Gs protein.

Nuclear Magnetic Resonance Detection of Increased Cortical GABA in Vigabatrin‐Treated Rats In Vivo

1H Nuclear magnetic resonance ([1H]NMR) spectroscopy was used to detect elevation of gamma-aminobutyric acid (GABA) in rat brain after administration of the antiepileptic drug vigabatrin (VGB). Rats were treated for 3 weeks with VGB added to their drinking water to deliver a dose of 250 mg/kg body weight per day. NMR spectroscopy was performed noninvasively in vivo, and a GABA concentration of 6.0 +/- 2.3 mmol/kg wet weight (mean +/- SD, n = 5) was measured. GABA could not be detected in control animals in vivo. Postmortem GABA levels of 1.3 +/- 0.5 and 4.5 +/- 1.0 mmol/kg (mean +/- SD, n = 5) were measured in perchloric acid extracts of frozen brain from control and treated animals, respectively. Noninvasive measurement of increased cerebral GABA should allow detailed studies of the pharmacology of GABA-increasing drugs in vivo. With future developments, these measurements may be feasible in human subjects.

Picrotoxin and pentylene tetrazole induced seizure activity in pyridoxine-deficient rats

Computerized electroencephalography and thalamic ventro-posterior lateral (VPL) unit activities were recorded from pyridoxine-deficient and pair-fed pyridoxine-supplemented adult male rats. Pyridoxine-deficient animals exhibited slow electroencephalograms (EEG) represented by the dominance of delta activity and reduced seizure thresholds to local (VPL) application of either picrotoxin or pentylene tetrazole. Frequency and amplitude of thalamic VPL unit activity were significantly reduced in pyridoxine-deficient rats as compared to pyridoxine-supplemented controls. Pyridoxine-deficient rats exhibited irregular unit activity with frequent bursts and electrosilent periods in response to local (VPL) picrotoxin or pentylene tetrazole microinjections. They also exhibited severe seizure discharge activity of prolonged duration at any given dose of either picrotoxin or pentylene tetrazole. This was represented by significantly increased burst frequency, burst duration and reduced seizure latencies. Unit activity was transformed into burst discharge activity with intermittent electrosilent zones during picrotoxin or pentylene tetrazole epileptogenesis. Cerebral gamma aminobutyric acid (GABA) level was reduced and glutamate concentration increased in pyridoxine-deficient rats when compared with pyridoxine-supplemented controls. Local (VPL) microinjection of GABA or pyridoxine induced neuronal recovery in both convulsant-treated normal and pyridoxine-deficient rats. Neuronal recovery was however delayed in pyridoxine-deficient rats. Neuronal recovery was associated with a significant increase in EEG background frequency and reduction in delta frequencies in the EEG records of both normal and pyridoxine-deficient rats. Reduced seizure threshold and delayed neuronal recovery are related to the significantly reduced brain regional GABA and elevated glutamate levels in pyridoxine-deficient rats.

Pharmacology and Clinical Pharmacology of Vigabatrin

Vigabatrin is an enzyme-activated, irreversible inhibitor of gamma-aminobutyric acid (GABA) aminotransferase, which causes a marked increase in cerebral GABA concentration and a resulting anticonvulsant action. Recovery from its effects requires the synthesis of new enzyme, and this may take several days following a single dose. The pharmacokinetics of vigabatrin are not a good guide to its duration of action. It is cleared rapidly by renal elimination (giving a plasma half-life of approximately 7 to 9 hours), and therefore the effect of the drug long outlasts its presence in the body. Plasma drug level monitoring is therefore of little value in regulating vigabatrin therapy. The drug is not bound to plasma proteins. Interactions with other drugs would not be expected because of its predominant renal elimination and its lack of protein binding. Also, vigabatrin does not induce liver enzymes, as do many of the standard antiepileptic drugs. In several trials, however, a small but significant reduction in phenytoin levels has been seen following the addition of vigabatrin to the antiepileptic medication. The mechanism for this reduction in phenytoin levels has not yet been elucidated, though it does not appear to be of clinical significance.

Increased γ‐Aminobutyric Acid Receptor Function in the Cerebral Cortex of Myoclonic Calves with an Hereditary Deficit in Glycine/Strychnine Receptors

Inherited congenital myoclonus (ICM) of Poll Hereford cattle is a neurological disease in which there are severe alterations in spinal cord glycine-mediated neurotransmission. There is a specific and marked decrease, or defect, in glycine receptors and a significant increase in neuronal (synaptosomal) glycine uptake. Here we have examined the characteristics of the cerebral gamma-aminobutyric acid (GABA) receptor complex, and demonstrate that the malfunction of the spinal cord inhibitory system is accompanied by a change in the major inhibitory system in the cerebral cortex. In synaptic membrane preparations from ICM calves, both high-and low-affinity binding sites for the GABA agonist [3H]muscimol were found (KD = 9.3 +/- 1.5 and 227 +/- 41 nM, respectively), whereas only the high-affinity site was detectable in controls (KD = 14.0 +/- 3.1 nM). The density and affinity of benzodiazepine agonist binding sites labelled by [3H]diazepam were unchanged, but there was an increase in GABA-stimulated benzodiazepine binding. The affinity for t-[3H]butylbicyclo-o-benzoate, a ligand that binds to the GABA-activated chloride channel, was significantly increased in ICM brain membranes (KD = 148 +/- 14 nM) compared with controls (KD = 245 +/- 33 nM). Muscimol-stimulated 36Cl- uptake was 12% greater in microsacs prepared from ICM calf cerebral cortex, and the uptake was more sensitive to block by the GABA antagonist picrotoxin. The results show that the characteristics of the GABA receptor complex in ICM calf cortex differ from those in cortex from unaffected calves, a difference that is particularly apparent for the low-affinity, physiologically relevant GABA receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

Subunit selectivity and epitope characterization of mAbs directed against the GABAA/benzodiazepine receptor.

mAbs bd 17, bd 24, and bd 28 raised against bovine cerebral gamma-aminobutyric acid (GABAA)/benzodiazepine receptors were analyzed for their ability to detect each of 12 GABAA receptor subunits expressed in cultured mammalian cells. Results showed that mAb bd 17 recognizes epitopes on both beta 2 and beta 3 subunits while mAb bd 24 is selective for the alpha 1 subunit of human and bovine, but not of rat origin. The latter antibody reacts with the rat alpha 1 subunit carrying an engineered Leu at position four, documenting the first epitope mapping of a GABAA receptor subunit-specific mAb. In contrast to mAbs bd 17 and bd 24, mAb bd 28 reacts with all GABAA receptor subunits tested but not with a glycine receptor subunit, suggesting the presence of shared epitopes on subunits of GABA-gated chloride channels.

Anti-convulsant effects by reduced glutathione and related aminoacids in rats treated with isoniazid

Rats were treated with different doses of isoniazid (INH) causing convulsions. Lethal dose (DL 50) and effective convulsant dose (ED 50) were calculated. Reduced glutathione (GSH) and related aminoacids were administered to rats receiving INH: the latency and duration of convulsions were recorded; cerebral gamma-aminobutyric acid (GABA) concentrations were determined in rats receiving INH and an association of GSH and INH. GSH and its related aminoacids as cysteine and glycine greatly decreased the duration of INH-induced seizures, while glutamic acid did not protect against convulsions caused by INH. Furthermore, INH causes a decrease in cerebral GABA levels to about half and GSH repeated pretreatment did, however, not prevent the INH induced decline of GABA content: hence, the anti-convulsant effect of GSH can not be ascribed to the restoration of normal levels of anti-epilectically acting GABA, but can be attributed to cysteine and glycine, aminoacids linked to GSH.

V. Cerebral cortical GABA and benzodiazepine binding sites in genetically seizure prone rats

Adult male and female genetically seizure-prone rats were assesed for sound-induced seizures. Heterozygous control groups were compared with mild seizure (designated GEPR 3) and severe seizure animals (GEPR 9). Groups of animals were killed and crude synaptosome fractions (P 2) prepared from freshly dissected cerebral cortices. Binding sites for gamma-aminobutyric acid (GABA) were assessed by [ 3H]-muscimol in the absence or presence of excess GABA and/or pentobarbital. Binding sites for benzodiazepines were assessed by [ 3H]-flunitrazepam in the presence of absence of clonazepam. Compared to controls, GEPR 3 animals had a modest increase and GEPR 9 animals a larger increase in Bmax for both high and low affinity GABA sites, with no change in Kd. Chloride-dependent, barbiturate-enhanced GABA binding (increased Bmax) was observed in all conditions and groups. Likewise benzodiazepine binding (Bmax) increased slightly in GEPR 9 animals. There were no observed changes in binding sites for a survey of biogenic amines. Seizure-prone animals appear to have compensatory denervation-like supersensitivity for their most prominent inhibitory receptor, which may or may not be linked to the seizure event.

GABA-Agonist Therapy for Alzheimerʼs Disease

Evidence suggesting a reduction of cerebral gamma-aminobutyric acid (GABA) neurons in Alzheimer's disease has been reported. To evaluate the possible contribution of GABA system dysfunction to the intellectual decline associated with this disorder, a controlled therapeutic trial of a potent and specific GABA agonist, THIP [4,5,6,7-tetrahydroisoxazolo(5,4,-c)pyridin-3-ol], was undertaken. Six Alzheimer patients with mild to moderately severe dementia and low spinal-fluid GABA levels received THIP at maximum individually tolerated dosage. No significant change in cognitive function could be discerned, despite attainment of dose levels that produced centrally mediated adverse effects similar to those of other GABA agonists. The results support the views that pharmacologic attempts to stimulate central GABA-mediated synaptic function may not confer therapeutic benefit to patients with Alzheimer's disease and that a GABA system deficit may not serve as a critical determinant of the dementia that characterizes this disorder.

Studies on the interaction between cerebral 5-hydroxytryptamine and gamma-aminobutyric acid in the mode of action of diazepam in the rat.

The effect of the benzodiazepine, diazepam, administered for 7 days in doses between 1.25 and 5 mg kg-1 was studied on the turnover of 5-hydroxytryptamine (5-HT) in rat cerebral cortex. 5-HT turnover was assessed by calculating the ratio of the concentration of the major metabolite 5-hydroxyindoleacetic acid (5-HIAA) to that of 5-HT (i.e., 5-HIAA:5-HT). Diazepam (2.5 and 5 mg kg-1 i.p. daily for 7 days) significantly reduced cerebral cortical 5-HT turnover. The effect of manipulating cerebral gamma-aminobutyric acid (GABA) mechanisms on this action of diazepam was studied. Treatment of animals with a subconvulsive dose of picrotoxin (3 mg kg-1 i.p.) reversed the fall in cortical 5-HT turnover seen following diazepam. In contrast, however, treatment with the GABA transaminase inhibitors, amino-oxyacetic acid (25 mg kg-1) or ethanolamine-O-sulphate (250 mg kg-1, 7 days) which elevated cerebral GABA concentrations, enhanced the reduction in cortical 5-HT turnover following diazepam. Focal injection of picrotoxin (0.1 micrograms) into the region of the dorsal raphé nucleus reversed the decrease in cortical 5-HT turnover caused by diazepam. The hypothesis that doses of diazepam which result in total plasma concentrations comparable to those observed in man produce a reduction in 5-HT turnover mediated via GABA neurones is discussed.

Effect of sodium-valproate on CSF GABA, cAMP, cGMP and homovanillic acid levels in men

Sodium valproate which seems to have an inhibitory effect on GABA-T and on succinic semialdehyde-dehydrogenase was shown to cause an increase of cerebral GABA (gamma-aminobutyric acid) concentration in animal studies [19]. The present investigations were performed to examine whether a possible influence on the cerebral GABA and dopamine metabolism and on the cyclic 3',5'-adenosine-monophosphate (cAMP) and cyclic 3',5'-guanosine-monophospnate (cGMP) system may be detectable in human beings. For this purpose the concentrations of GABA, homovanillic acid (HVA), prolactin, cAMP and cGMP were measured using OC-MS detection for GABA determination, radio-immunoassays for the measurements of cAMP, cGMP and prolactin and fluorescence detection for quantification of homovanillic acid. Before and after a three week period of treatment with valproate CSF was obtained by lumbar puncture. The results indicated a significant elevation of GABA, cAMP and homovanillic acid and a slight increase of cGMP in CSF after treatment with valproate, whereas no changes were observed in plasma prolactin, cAMP and cGMP concentrations. Thus Valproate seems to have an influence on GABA and dopamine metabolism and on the cAMP-system in man.

Responses of the guinea-pig isolated olfactory cortex slice to gamma-aminobutyric acid recorded with extracellular electrodes.

1. Potential changes between the pial and cut surfaces of slices of guinea-pig olfactory cortex in vitro produced by gamma-aminobutyric acid (GABA) were recorded with extracellular electrodes. 2. GABA, superfused over the pial surface (0.1 to 10 mM), produced a pial-negative potential deflection, accompanied by inhibition of the postsynaptic response to lateral olfactory tract (LOT) stimulation. 3. This effect was replicated by the following compounds (potency relative to GABA = 1, in brackets): 3-aminopropanesulphonic acid (5.3), epsilon-aminovaleric acid (0.07), beta-alanine (0.07), beta-amino-nibutyric acid 0.05), epsilon-aminocaproic acid, alpha-amino-isobutyric acid, L-leucine (less than 0.02). 4. L-Glutamate (1 to 10 mM) produced a very large surface negative shift, with relatively less synaptic inhibition. Glycine (1 to 10 mM) produced less surface negatively, accompanied by synaptic inhibition. 5. Responses to GABA were antagonized more effectively than those to glycine by bicuculline (3 to 30 micrometer) and picrotoxin (1 to 30 micrometer). Strychnine (1 to 10 micrometer) incompletely inhibited responses to glycine. 6. It is concluded that, while the locus within the slice of these effects is uncertain, the preparation may be useful for testing the interaction of drugs with cerebral GABA receptors.

Gamma-aminobutyric acid (GABA) uptake by the developing mouse brain in vivo

(1) Cerebral uptake of GABA was studied following the subcutaneous administration of different doses of the amino acid to mice at various prenatal and postnatal stages. (2) The cerebral level of GABA could be significantly increased at all ages studied, but the doses injected in order to produce a measurable net uptake needed to be higher in more mature animals. High doses of GABA were toxic for immature mice. (3) In pregnant females injected with doses lethal for newborn mice, GABA was taken up by the placenta, reached the embryonic blood and was taken up by the embryonic brain to a greater extent than at any postnatal stage studied. GABA concentration decreased more rapidly in maternal plasma than in the placenta or fetal plasma. (4) The rate of excretion and metabolism of GABA was greater in mature mice, where plasma levels decreased much more rapidly than in immature animals. (5) Large doses of γ-amino-β-hydroxybutyric acid inhibited the metabolic degradation and the rate of excretion of exogenous GABA. Moreover, γ-amino-β-hydroxybutyric acid caused a statistically significant inhibition of GABA uptake by brain. (6) The concept of the blood-brain barrier to GABA and of its evolution during development is discussed. It is concluded that decreased permeability of the blood-brain interface to GABA is at best one of the factors contributing to the reduced elevation of cerebral GABA levels observed in mature animals after parenteral administration. Other important factors are increased rates of metabolic breakdown, of excretion, and possibly of active transport from the brain.

Anticonvulsant properties of hydroxylamine and elevation of cerebral gamma-aminobutyric acid in cats.

SummaryHydroxylamine when administered to immobilized cats in acute experiments in doses of 10-20 mg/kg markedly reduced duration and spread of electrically-induced afterdischarges while increasing cerebral levels of γ-aminobutyric acid. These findings increase the probability that a causal relationship may exist between metabolism of γ-aminobutyric acid in a particular cerebral area and its excitability.